Registry for patients with cardiomyopathies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The DZHK TORCH-Plus registry is designed to collect clinical data and biological samples from patients with various types of non-ischemic cardiomyopathies. This multi-center initiative aims to expand the existing registry by increasing the number of participants to better understand the prevalence and characteristics of these conditions. The study includes four main modules focusing on clinical phenotyping, genomics, inflammation, and biomarkers, which will facilitate innovative research in cardiomyopathies. Patients will be followed over time to gather comprehensive data on their health outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Non-ischemic structural cardiomyopathies
* Age ≥ 18 or ≤ 80 years
* The patient is able to understand the declaration of consent and to sign it dated
* At least one of the following diagnoses depending on the specific TORCH-

Plus inclusion / exclusion - SOP:

Dilated Cardiomyopathy (DCM)

* family / genetic
* inflammatory / persistent myocarditis
* idiopathic (after exclusion secondary cause)
* left sided systolic dysfunction (EF ≤ 45%)

Left ventricular hypertrophy

* sarcomere hypertrophic cardiomoypathia (HCM, HOCM)
* amyloid (AL: light chains, TTR: transthyretin, wild type)

Left ventricular non-compaction cardiomyopathy (LVNC)

Arrhythmogenic right ventricular cardiomyopathy (ARVC / D)

Exclusion Criteria:

The following exclusion criteria have been defined and must be taken from the TORCH-Plus specific inclusion / exclusion - SOP in detail:

* Age: \<18 years or\> 80 years
* Patient has other (cardiac) previous illnesses:

  * uncontrollable arterial hypertension
  * primary pulmonary arterial hypertension
  * radiation therapy in the chest area
  * addiction (drug or alcohol abuse)
  * life expectancy \<1 year due to non-cardiological pre-existing conditions
  * significant heart valve disease
  * ischemic diseases and severe congenital heart diseases (including VSD, Fallot tetralogy, Ebstein anomaly)
  * chemotoxic cardiomyopathy
  * condition after myocarditis
  * combination of several traditional risk factors (e.g. hypertension and diabetes mellitus)
  * advanced chronic non-cardiac disease (e.g. chronic hepatitis or HIV)
  * Tachymyopathy

Where it's running

• University Hospital Heidelberg - Clinic of Cardiology, Angiology and Pneumology
  Heidelberg, Baden-Wurttemberg, Germany Recruiting

Study contacts

• Study coordinator: Farbod Sedaghat-Hamendani, Dr.
• Email: Farbod.Sedaghat-Hamedani@med.uni-heidelberg.de
• Phone: +496221/56-8676

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry and biobank for arrhythmogenic ventricular cardiomyopathy

  This study is trying to gather information and samples from people with arrhythmogenic ventricular cardiomyopathy and their families to better understand the genetic causes of the condition and improve early diagnosis for those at risk.

  Recruiting at 2 sites Mayo Clinic · Rochester, Minnesota and 1 other locations · NCT03049254

• See if stopping heart failure meds is safe for super-responders with non-ischemic cardiomyopathy and CRT

  This trial tests whether stopping heart failure medications is safe in patients with non-ischemic cardiomyopathy who have had a strong positive response to CRT and meet specific genetic and imaging criteria.

  Recruiting at 4 sites Phase 4 Institut d'Investigació Biomèdica de Bellvitge · L'Hospitalet de Llobregat, Barcelona and 3 other locations · NCT07851779

• Left bundle branch area pacing with multimodal guidance vs. conventional pacing for heart failure with complete left bundle branch block

  A multicenter trial tests whether using multimodal data to guide left bundle branch area pacing helps people with heart failure and complete left bundle branch block, compared with traditional biventricular pacing.

  Recruiting Second Affiliated Hospital of Nanchang University · Nanchang, Jiangxi · NCT07814612

• MRI-guided risk-based pacing for heart failure with reduced ejection fraction

  This study tests whether left bundle branch pacing without a defibrillator works as well as traditional CRT with defibrillator in people with a specific heart failure and MRI-detected low risk of scar.

  Recruiting Velammal Medical College Hospital and Research Institute · Madurai, Tamil Nadu · NCT07791407

• Acoramidis for ATTR-CM: Cardiac Imaging Study

  This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.

  Recruiting Phase 4 Eidos Therapeutics, a BridgeBio company · St Louis, Missouri · NCT07695701

• FAPI PET/CT imaging in arrhythmogenic right ventricular cardiomyopathy

  This study will test whether a PET/CT scan using a 68Ga-DOTA-SA-FAPI tracer can detect active scarring in adults with ARVC and provide information beyond standard heart imaging.

  Recruiting Istanbul University - Cerrahpasa · Istanbul, Fatih · NCT07563660

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.